These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 32008237)

  • 1. Adaptive Designs: Results of 2016 Survey on Perception and Use.
    Hartford A; Thomann M; Chen X; Miller E; Bedding A; Jorgens S; Liu L; Chen L; Morgan C
    Ther Innov Regul Sci; 2020 Jan; 54(1):42-54. PubMed ID: 32008237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive Design: Results of 2012 Survey on Perception and Use.
    Morgan CC; Huyck S; Jenkins M; Chen L; Bedding A; Coffey CS; Gaydos B; Wathen JK
    Ther Innov Regul Sci; 2014 Jul; 48(4):473-481. PubMed ID: 30235570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
    Cerqueira FP; Jesus AMC; Cotrim MD
    Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
    Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
    Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov.
    Bothwell LE; Avorn J; Khan NF; Kesselheim AS
    BMJ Open; 2018 Feb; 8(2):e018320. PubMed ID: 29440155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stakeholder perspectives on adaptive clinical trials: a scoping review.
    Madani Kia T; Marshall JC; Murthy S
    Trials; 2020 Jun; 21(1):539. PubMed ID: 32552852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradigms for adaptive statistical information designs: practical experiences and strategies.
    Wang SJ; Hung HM; O'Neill R
    Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DIA's Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for "Less Well-understood" Adaptive Designs.
    Miller E; Gallo P; He W; Kammerman LA; Koury K; Maca J; Jiang Q; Walton MK; Wang C; Woo K; Fuller C; Jemiai Y
    Ther Innov Regul Sci; 2017 Jan; 51(1):77-88. PubMed ID: 30235997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials.
    Dimairo M; Julious SA; Todd S; Nicholl JP; Boote J
    Trials; 2015 Dec; 16():585. PubMed ID: 26700741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
    Sato A; Shimura M; Gosho M
    J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive clinical trials: progress and challenges.
    Coffey CS; Kairalla JA
    Drugs R D; 2008; 9(4):229-42. PubMed ID: 18588354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
    Mauer M; Collette L; Bogaerts J;
    Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits, challenges and obstacles of adaptive clinical trial designs.
    Chow SC; Corey R
    Orphanet J Rare Dis; 2011 Nov; 6():79. PubMed ID: 22129361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An objective re-evaluation of adaptive sample size re-estimation: commentary on 'Twenty-five years of confirmatory adaptive designs'.
    Mehta C; Liu L
    Stat Med; 2016 Feb; 35(3):350-8. PubMed ID: 26757953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.
    Ryeznik Y; Sverdlov O; Hooker AC
    AAPS J; 2017 Dec; 20(1):24. PubMed ID: 29285730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.
    Lestini G; Dumont C; Mentré F
    Pharm Res; 2015 Oct; 32(10):3159-69. PubMed ID: 26123680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
    Hague D; Townsend S; Masters L; Rauchenberger M; Van Looy N; Diaz-Montana C; Gannon M; James N; Maughan T; Parmar MKB; Brown L; Sydes MR;
    Trials; 2019 May; 20(1):294. PubMed ID: 31138292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing Challenges and Opportunities of "Less Well-Understood" Adaptive Designs.
    He W; Gallo P; Miller E; Jemiai Y; Maca J; Koury K; Fan XF; Jiang Q; Wang C; Lin M
    Ther Innov Regul Sci; 2017 Jan; 51(1):60-68. PubMed ID: 30235991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.